Related Experiment Video
Updated: Jul 10, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Combined-modality therapy for rectal cancer: future prospects.
Brian G Czito1, Christopher G Willett, Johanna C Bendell
1Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. czito@radonc.duke.edu
Clinical Colorectal Cancer
|October 20, 2007
Summary
Advances in rectal cancer treatment, including surgery, radiation, and chemotherapy, have improved patient outcomes. Newer agents are now being studied in neoadjuvant therapy for advanced rectal cancer.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Rectal cancer management has evolved significantly with progress in surgery, radiation therapy, and chemotherapy.
- These therapeutic advancements have led to enhanced local control, survival rates, and patient quality of life.
- Recent developments in chemotherapy and targeted agents have further improved disease-free and overall survival in advanced colorectal cancer.
Purpose of the Study:
- To review the evolution of rectal cancer management.
- To highlight recent advancements in systemic therapy for advanced colorectal cancer.
- To discuss the investigation of novel agents in neoadjuvant rectal cancer therapy.
Main Methods:
- Literature review of surgical, radiation, and chemotherapeutic advancements in rectal cancer.
- Analysis of recent studies on systemic therapies for advanced colorectal cancer.
- Examination of ongoing research into neoadjuvant therapies incorporating newer agents.
Main Results:
- Significant improvements in local control, survival, and quality of life have been achieved through multimodal treatment strategies.
- Advanced systemic therapies have demonstrated efficacy in improving disease-free and overall survival for advanced colorectal cancer.
- Emerging research is exploring the integration of novel chemotherapeutic and targeted agents with radiation therapy for neoadjuvant rectal cancer treatment.
Conclusions:
- Modern multimodal approaches have substantially improved outcomes for rectal cancer patients.
- Systemic therapies continue to advance, offering better survival for advanced disease.
- Neoadjuvant therapy for rectal cancer is evolving with the incorporation of newer agents, potentially enhancing treatment efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...